Company profile: Tubulis
1.1 - Company Overview
Company description
- Provider of chemotherapeutic medications for cancer and chronic disorders, developing disease-matched protein-drug conjugates (ADCs) using proprietary P5 conjugation chemistry and the Tubutecan linker-payload platform. Products include TUB-030 targeting 5T4 in solid tumors for long-lasting anti-tumor activity and TUB-040 targeting NaPi2b in ovarian and lung cancer for stable, potent delivery.
Products and services
- Specifically Matched Protein-Drug Conjugates: Tubulis develops chemotherapeutic medications by merging proprietary technology with disease-specific biology to create precisely matched protein-drug conjugates enabling clinician-directed treatment of cancer and chronic disorders (proprietary)
- TUB-040: A therapy targeting NaPi2b overexpressed in ovarian and lung cancer, employing the Tubutecan linker-payload platform to achieve stable, potent delivery to tumor cells (targeted)
- TUB-030: An ADC targeting the cancer antigen 5T4 expressed in solid tumors, utilizing proprietary P5 conjugation chemistry to enable long-lasting anti-tumor activity
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Tubulis
Dermira
HQ: United States
Website
- Description: Provider of specialty biopharmaceutical development and commercialization of innovative dermatology therapies. Focused on bringing differentiated products to dermatologists and patients, with a portfolio of five product candidates. Founded in 2010, headquartered in Menlo Park, California.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dermira company profile →
Alentis Therapeutics
HQ: Switzerland
Website
- Description: Provider of CLDN1-targeted therapeutics for CLDN1+ cancers and fibrosis. This clinical-stage Swiss-French biotech develops anti-CLDN1 antibodies and ADCs, including ALE.C04 (mAb for CLDN1+ tumors that opens the collagen barrier), Lixudebart (mAb to reverse liver, kidney, and lung fibrosis), and preclinical ADCs ALE.P02 (delivers a tubulin inhibitor) and ALE.P03 (delivers a topoisomerase I inhibitor) into tumor cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alentis Therapeutics company profile →
Cue Biopharma
HQ: United States
Website
- Description: Provider of biologic immunotherapies and a platform for cancer, chronic viral infections, and autoimmune diseases. Offerings include CUE-101 activating tumor-specific T cells against HPV16+ head and neck cancer; CUE-102/103 targeting additional tumor antigens and HLA alleles in solid tumors; CUE-200 activating virus-specific CD8+ T cells; CUE-300 inhibiting autoreactive CD4+ and enhancing regulatory T cells; CUE-301 for type 1 diabetes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cue Biopharma company profile →
Immunovant
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical offerings focused on enabling normal lives for patients with autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunovant company profile →
Vir Biotechnology
HQ: United States
Website
- Description: Provider of immunology-based products to treat and prevent infectious diseases and other serious conditions, including Phase 2 tobevibart + elebsiran for chronic hepatitis delta and elebsiran + PEG-IFN-α for chronic hepatitis B; Phase 1 VIR-1388 for HIV prevention; and preclinical candidates VIR-8190 (RSV & hMPV), VIR-2981 (influenza A/B), and VIR-1949 (pre-cancerous HPV lesions).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vir Biotechnology company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Tubulis
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Tubulis
2.2 - Growth funds investing in similar companies to Tubulis
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Tubulis
4.2 - Public trading comparable groups for Tubulis
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →